Voriconazole: An evaluation of activity and use

Journal of Infectious Disease Pharmacotherapy

Volumn 6, Issue 2, 2003, Pages 15-37

  Van Loo, Dean ^a,b  

^a Ferris Stt Univ Coll of Pharmacy   (United States)

^b BRONSON METHODIST HOSPITAL   (United States)

Author keywords

Antifungal; Efficacy; Safety; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ERGOT ALKALOID; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; BRAIN ABSCESS; CANDIDA; CHILL; CLINICAL TRIAL; COCCIDIOIDES IMMITIS; CRYPTOCOCCUS NEOFORMANS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HALLUCINATION; HEADACHE; HISTOPLASMA CAPSULATUM; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PAECILOMYCES LILACINUS; PATIENT MONITORING; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; PNEUMONIA; PSORIASIS; REVIEW; SCEDOSPORIUM; STEVENS JOHNSON SYNDROME; TACHYCARDIA; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; ZYGOMYCETES;

EID: 0041830540     PISSN: 10687777     EISSN: None     Source Type: Journal    
DOI: 10.1300/J100v06n02_02     Document Type: Review

References (102)

1. Stevens DA, Bennett JE. Antifungal Agents. In: Mandell GL, Bennett JE and Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstone. 2000:448-59.
2. Pfaller MA, messer SA, Hollid RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents and Chemother. 2002;46:1723-7.
3. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature. Mycopathologia 2001;150:101-15.
4. Ernst EJ. Investigational antifungal agents. Pharmacotherapy. 2001;21:165S-74S.
5. Vfend™ [prescribing information]. New York, NY: Pfizer Inc. 2002
6. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents and Chemother. 2002;46:2546-53.
7. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. Clin Pharmacol Ther. 2002;42:395-402.
8. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol. 1997;97:663-5.
9. Poza G, Montoya J, Redondo C et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis. 2000;30:981-2.
10. Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol. 1998;36:1436-8.
11. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture based microbiological methods and management. J Clin Microbiol. 1999;37:1186-9.
12. Nesky MA, McDougal EC, Peacock JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis. 2000;31:673-7.
13. Reis A, Sundmacher R, Tintelnot K et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voficonazole. Br J Ophthalmol. 2000;84:932-3.
14. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-8.
15. Walsh TJ, Arguedas A, Driscoll T et al. Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-17.
16. Tomaszewski K, Purkins L. The pharmacokinetics (PK) and safety of sulphobutylether-b-cyclodextrin (SBECD). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-23.
17. Tan KK, Wood N, Weil A. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-16.
18. Ramesh MS, Baskaran I, Ganesan LT et al. Postantifungal effect of older and newer antifungal agents on Aspergillus fumigatus and Candida albicans. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-105.
19. Garcia MT, Llorente MT, Lima JE et al. Activity of voriconazole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis. 1999;31:501-4.
20. Kelpser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother. 2000;44:1917-20.
21. Ernst EJ, Yodoi K, Roling EE, Klepser ME. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time kill methods. Antimicrob Agents Chemother. 2002;46:578-81.
22. Manavathu EK, Curight JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother. 1998;42:3018-21.
23. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-71.
24. Tan KC, Brayshaw N, Oakes M. Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-105.
25. Johnson EM, Szekely A, Warnock. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741-5.
26. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother, 1998;42:389-92.
27. Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother. 1998;42:91-4.
28. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemoter. 1998;42:531-3.
29. Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol. 1998;36:433-6.
30. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother. 2002;46:1032-7.
31. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother. 2001;45:605-7.
32. Hayette MP, Amadore A, Seidel L et al. Comparative in vitro activity of amphotericin B, itraconazole, voriconazole and posaconazole against Aspergillus fumigatus. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-105.
33. Espinel-Ingroff A, Bartlett M, Chaturvedi V et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp. NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother. 2001;45:1828-35.
34. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2002;46:556-7.
35. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terrus, with a head to head comparison to voriconazole. J Clin Microbiol. 1999;37:2343-5.
36. Pfaller MA, Diekema DJ, Messer SA et al. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents including the new triazoles posaconazole, ravuconazole, and voriconazole. J Clin Microbiol. 2002;40:1694-7.
37. Pfaller MA, Messer SA, Gee S et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol. 1999;37:870-2.
38. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida, spp. Antimicrob Agents Chemother. 1998;42:161-3.
39. Alacala L, Pelaez T, Marin M et al. Antifungal susceptibility of yeasts responsible for bloodstream infections. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 225.
40. Girmenia C, Tuccinardi C, Santilli S et al. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies. J Antimicrob Chemother. 2000;46:479-83.
41. Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A, Jones RN. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol. 2000;38:3715-7.
42. Hoban DJ, Karlowsky JA, Ritchie K, Palatnick LP, Zhanel GG. Azole resistance in Candida species: results of a two year Canadian national surveillance study. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 229.
43. Ruhnke M, Schmid-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1997;41:575-7.
44. Pfaller MA, Jones RN, Doern GV et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis. 1999;35:19-25.
45. Chavez M, Bernal S, Valverde A et al. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother. 1999;44:697-700.
46. Bhargava P, Vazquez JA. Amphotericin B-resistant Candida krusei? A comparison of standardized testing and time-kill studies. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 924.
47. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;3254-9.
48. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol. 2001;39:525-32.
49. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and-resistant Candida species. Antimicrob Agents Chemother. 1997;41:1840-2.
50. Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazle, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother. 2000;46:338-40.
51. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39:954-8.
52. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent against emerging and lesscommon mold pathogens. Antimicrob Agents Chemother. 1997;41:841-3.
53. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 1998;17:573-5.
54. Paphitou N, Paetznick V, Ostrosky-Zeichner L. In vitro activity of investigational triazoles against Fusarium spp.: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-573.
55. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother, 1999;43:149-51.
56. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001;45:2151-3.
57. Meletiadis J, Meis JF, Mouton JW et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62-8.
58. Pfaller MA, Zhang J, Messer SA et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 1999;43:169-71.
59. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother. 1998;42:471-2.
60. Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis. 2000;19:317-9.
61. Mondon P, Petter R, Amalfitano G et al. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother. 1999;43:1856-61.
62. Ren-Kai L, Ciblak MA, Nordoff N et al. In vitro activities of voriconazole, itraconazole, and amphotericin B, against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother. 2000;44:1734-6.
63. McGinnis MR, Pasarell L, Sutton DA et al. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 1997;41:1832-4.
64. Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole, and terbinafine. Br J Dermatol. 2000;142:758-65.
65. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol. 2001;39:385-8.
66. Fernandez-Torres B, Carrillo AJ, Martin E et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother. 2001;45:2524-8.
67. Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother. 2001;48:919-21.
68. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother. 2002;46:1581-2.
69. Huczko E, Minassian B, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium, and Fusarium isolates. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-810.
70. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998;36:198-202.
71. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:2865-8.
72. Chandrasekar PH, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother. 2000;45:673-6.
73. George D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 1996;40:86-91.
74. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 1997;41:696-8.
75. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother. 1997;41:13-6.
76. Ghannoum MA, Okogbule-Wonodi I, Bhat N, Sanati H. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in a neutropenic guinea pig model. J Chemother. 1999;11:34-9.
77. Sugar AM, Liu XP. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother. 2001;45:601-4.
78. Reyes GH, Long L, Hossain M, Ghannoum MA. Evaluation of voriconazole efficacy in the treatment of murine l'usariosis. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-1604.
79. Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis. 2000;32:331-2.
80. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med. 1998;157:1694-6.
81. Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol. 2000;38:3900-1.
82. Verweij PE, van den Bergh MF, Rath PM, de Pauw BE, Voss A, Meis JF. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol. 1999;37:1606-9.
83. Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Waizgiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis. 2001;33:777-9.
84. Munoz P, Marin M, Tornero P et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis. 2000;31:1499-501.
85. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and Iluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin infect Dis. 2001;33:1447-54.
86. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-34.
87. Apisarnthanarak A, Little JR, Tebas P. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med. 2002;346:1746.
88. Walsh TJ, Lee J, Dismukes WE. Decisions about voriconazole versus liposomal amphotericin B. N Engl J Med. 2002;346:1499.
89. Herbrecht R, Denning DW, Patterson TF et al. Open, randomized comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract J-680.
90. Tomaszewski K, Purkins L. Visual effects with voriconazole. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-639.
91. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. Voriconazole ptentiates warfarin-induced prolongation of prothrombin time. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 846.
92. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. Voriconazole does not affect the pharmacokinetics of digoxin. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 849.
93. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. The pharmacokinetics of voriconazole and its effect on prednisolone disposition. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 842.
94. Ghahramani P, Romero AJ, Lant AF, Allen MJ. The effect of voriconazole on the pharmacokinetics of cyclosporin. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 845.
95. Ghahramani P, Purkins L, Kleinermans D, Love ER, Nichols DJ. No significant pharmacokinetic interactions between voriconazole and indinavir. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 848.
96. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 844.
97. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. Effect of omeprazole on the pharmacokinetics of voriconazole. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 843.
98. Ghahramani P, Purkins L, Love ER, Eve MD, Fielding A, Nichols DJ. Drug interactions between voriconazole and phenytoin. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON. 2000 Sept 17-20; Abstract 847.
99. Singh N, Zhang S, Gayowski T, Venkataramanan R. Voriconazole inhibition of tacrolimus metabolism after liver transplantation and in human liver microsomes. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-21.
100. Wood N, Abel S, Fielding A, Nichols DJ, Bygrave E. Voriconazole does not affect the pharmacokinetics of mycophenolic acid. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-24.
101. Wood N, Tan K, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of tacrolimus. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-20.
102. Wood N, Tan K, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of omeprazole. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2001 Dec 16-19; Abstract A-19.